Southwest Securities: New crown epidemic affects performance, high-quality companies enter annual report window period
For stocks, please read Jin Qilin analyst research report, authoritative, professional, timely, and comprehensive, to help you tap potential potential opportunities! The new crown epidemic affects immediate performance, and high-quality companies enter the annual report window period![Southwest Securities Medical | 0202 Weekly]Source: Southwest Securities Medical Research 1, Investment Highlights Market Review: This week, the Biomedical Index rose by 0.3%, outperformed CSI 300 by about 4.Zero digits, of which the medical business has the largest increase of about 4.7%, medical services fell 3.5%. Overview of the epidemic situation: As of 24:00 on February 1, 2020, the National Health Commission has received 14,380 confirmed cases (including a total of 9,074 confirmed cases in Hubei Province), 2110 cases of severe cases, and 304 cases of progressive death.A total of 328 discharged patients were gradually cured, with a total of 19,544 suspected cases. The World Health Organization has announced that the epidemic has been escalated to “public health emergencies of international concern”, but at the same time said that there is no reason to restrict and interfere with international travel, and it is not recommended.Restrictions on travel.At present, the new coronavirus is generally susceptible to the population. The main mode of transmission is through droplets. The onset of fever is mainly manifested by fever. It can be combined with mild dry cough, fatigue, poor breathing, diarrhea and other symptoms. Runny nose, cough and other symptoms are rare., At present, the Health and Health Commission has issued the “Guidelines for the Prevention and Control of New Coronaviruses (First Edition)”.Industry policies: 1) Legally regulated infectious diseases of pneumonitis infected by new coronavirus: Pneumonia infected by new coronavirus is classified into “type B infectious diseases, and measures for prevention and control of type A infectious diseases are adopted.2) Medical Insurance Bureau’s temporary supplementary medical insurance payment for new pneumonia-covered drugs: Adopt a special reimbursement policy, and drugs and medical service items for new coronavirus treatment covers all temporarily replace the scope of medical insurance fund payment.3) Organize the resumption of production and scheduling of key material production enterprises for epidemic prevention and control: promptly organize the resumption of production of medical protective clothing, N95 masks, medical goggles, negative pressure ambulances, and related drugs used in response to the epidemic. Investment strategy: On the whole, pharmaceutical stocks have rebounded significantly, showing rich characteristics.Opinion of the Southwestern Medicine Team: Affected by the coronavirus pneumonia epidemic, the medical index rose by 0 in the week before the Spring Festival.3%, far exceeding the market 4.0%, very strong performance.According to the experience of SARS, the impact on the pharmaceutical industry is relatively limited in the medium and long term. Due to the high uncertainty of the epidemic event, the international pharmaceutical giants are not strong in research and development, but most companies such as Hualan Biological and Zhifei Biological have been involved in the flu vaccine; in the short term,, Masks (Ogilvy Medical, Zhende Medical, etc.), big infusions (Chenxin Pharmaceutical, Kelun Pharmaceutical, etc.), interferons (Anke Bio, Treasure Bio, etc.), forehead guns (Yuyue Medical)Etc.) The performance impact is relatively obvious. The first-quarter performance is likely to exceed expectations, but it is not 无锡桑拿网 recommended due to epidemic events.Entering February, it is the window period for annual and quarterly reports. It is necessary to configure the best window period for medicine before the quarterly report, otherwise miss one year again.There are two preliminary results: one of the second batch of volume purchases has landed, and the negative expectations are fulfilled; the other is that Changchun High-tech, Zhifei Biological and CXO’s 2019 performance forecasts have been released, continuing the high growth trend.What is the pharmaceutical strategy for 2020?Flowers bloom, equipment contends.Focus on three major directions: platform and innovative devices; high-quality stocks with consumer attributes; innovative drugs and their industrial chains (for details, please see the 2020 Pharmaceutical Industry Strategy Report).In terms 都市夜网 of performance certainty, we recommend Hengrui Medicine, Changchun High-tech, Zhifei Bio, etc .; in order of industry trends, we recommend WuXi AppTec, Kangtai Bio, Mindray Medical, etc.Specific investment strategies: 1) Fully focus on high-quality medical equipment and orthopedics, recommend Kailitai + Dabo Medical, focus on Aikang Medical + Chunli Medical, etc .; endoscopic diagnosis and treatment, focus on Nanwei Medical, etc .; cardiovascularIn the field, we mainly recommend Lepu Medical, Xinmai Medical, Qiming Medical, etc .; in the chemiluminescence field, we recommend Mindray Medical, Antu Bio, Mike Bio, Promen Technology, etc .; in the hemodialysis field, Jianfan Bio are recommended;Innovation is a strategic investment direction, with key recommendations: Hengrui Medicine (600276), WuXi AppTec (603259), China Biopharmaceutical (1177), Tiger Pharmaceuticals (300347) and Medicine Stone Technology (300725), etc.Consumption and medical service sectors that have limited impact and have sustained high growth performance. Key recommendations are: Changchun High-tech (000661), Zhifei Bio (300122), Kangtai Bio (300601), Aier Ophthalmology (300015), and Meinian Health (002044).4) Device benefit classification, diagnosis and treatment expansion and product technology upgrade, key recommendations: Mindray Medical (300760), Nanwei Medical (688029), Lepu医Therapy (300,003) and nine strong biological (300,406) and so on.5) In the field of pharmacies, we mainly recommend Dashenlin (603233) and ordinary people (603833). January recommended stable combinations: Hengrui Medicine (600276), WuXi AppTec (603259), Taige Medicine (300347), Changchun High-tech (000661), Zhifei Bio (300122), Kangtai Bio (300601), Lepu Medical(300003), Meinian Health (002044); Offensive small and medium-sized market value combination: Lingrui Pharmaceutical (600285), Kelly Thai (300326), Dongcheng Pharmaceutical (002675), Medicine Stone Technology (300725). Risk Warning: Changes in industry policies may exceed expectations, new product launches may enter or fall short of expectations, and product volume may be lower than expected. 1.The current epidemic situation is still severe, and the whole country can overcome the difficulties together1.1 newly confirmed and suspected case stabilized, but still cannot be taken lightly. Since the first appearance of the new coronavirus (2019-nCoV) in Wuhan, Hubei Province in December 2019, until February 1, 2020, the National Health and Medical Commission received 31Each province (autonomous region, municipality directly under the Central Government) and Xinjiang Production and Construction Corps have gradually reported 14,380 confirmed cases. There are currently 2110 severe cases, 304 cases of gradual death, 328 cases of discharged patients, and 19544 suspected cases.In Hong Kong, Macao and Taiwan, 14 cases were diagnosed in Hong Kong, 7 cases were diagnosed in Macao, and 10 cases were diagnosed in Taiwan.On January 30, 2020, a joint press conference of the World Health Organization announced that the epidemic was escalated to “public health emergencies of international concern” (public health emergencies of international concern), but also stated that there is currently no reason to restrict andIntervention in international travel, and WHO does not recommend any restrictions on travel. At present, the epidemic situation in Hubei Province is the worst. By 24:00 on February 1, 2020, Hubei Province had reported a total of 9,074 cases of new coronavirus infections (including 4109 in Wuhan), 215 patients have been discharged and 294 (including Wuhan224 cases).At present, 8565 patients are still being treated in the hospital, and they are all receiving isolation treatment at designated medical institutions. 48,571 people who have been in direct contact have been gradually tracked, and 43,121 people are still receiving medical observation. 1.2The population is generally susceptible to new coronavirus, fever is still the main symptom. The outbreak of 2019-nCoV belongs to the genus Coronavirus, which is an enveloped single-stranded RNA virus that can infect wild animals, pets, herds, andIn humans, patients present with different clinical symptoms ranging from the common cold to severe lung infections, such as the Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). At present, the new type of coronavirus is generally susceptible to the population, and it occurs in people with low immune function and normal immune function, which is related to the amount of virus exposure.For people with poor immune function, such as the elderly, pregnant women or patients with liver and kidney dysfunction, and people with chronic diseases, the condition is more severe after infection. The main transmission methods of the new coronavirus are droplet transmission, contact transmission (including self-implantation caused by hand contamination), and short-range transmission of respiratory aerosols of different sizes. At present, the onset of new coronavirus infection is mainly caused by fever, which can be combined with mild dry cough, fatigue, poor breathing, diarrhea and other symptoms, and runny nose, cough and other symptoms are rare.Some patients have mild onset symptoms without fever. They only show headache, palpitation, chest tightness, conjunctivitis, and mild soreness in the limbs or lower back muscles.Some patients experienced dyspnea after one week, and the disease progressed rapidly in severe cases.Most patients have a good prognosis, and a few patients are critically ill and even die. 1.3The new guidelines for the prevention and control of coronaviruses of the National Health and Medical Commission were officially released on February 1, 2020, and the National Health and Medical Commission issued the “New Coronavirus Prevention and Control Guidelines (First Edition)” for elderly, children, students, kindergartens (or schools)), Prevention and control of nursing homes, office premises, buildings, public places and home isolation issued related guidelines. 2 Investment strategies and key stocks 2.1 The current industry investment strategy is affected by the outbreak of coronavirus pneumonia, and the medical index rose by 0 in the week before the Spring Festival.3%, far exceeding the market 4.0%, very strong performance.According to the experience of SARS, the impact on the pharmaceutical industry in the medium and long term is relatively limited. Due to the uncertainty of the epidemic event, the international pharmaceutical giants are not strong in research and development, but the flu vaccine has many companies such as Hualan Biological and Zhifei Biological. In the short term,Pair of masks (Ogilvy Medical, Zhende Medical, etc.), big infusions (Chenxin Pharmaceutical, Kelun Pharmaceutical, etc.), interferons (Anke Bio, Tebao Bio, etc.), forehead guns (Yueyue Medical, etc.)) And other performance effects are relatively obvious, the first quarter performance is likely to exceed expectations, but not recommended due to epidemic events.Entering February, it is the window period for annual and quarterly reports. It is necessary to configure the best window period for medicine before the quarterly report, otherwise miss one year again.There are two preliminary results: one of the second batch of volume purchases has landed, and the negative expectations are fulfilled; the other is that Changchun High-tech, Zhifei Biological and CXO’s 2019 performance forecasts have been released, continuing the high growth trend.What is the pharmaceutical strategy for 2020?Flowers bloom, equipment contends.Focus on three major directions: platform and innovative devices; high-quality stocks with consumer attributes; innovative drugs and their industrial chains (for details, please see the 2020 Pharmaceutical Industry Strategy Report).In terms of performance certainty, we recommend Hengrui Medicine, Changchun High-tech, Zhifei Bio, etc .; in order of industry trends, we recommend WuXi AppTec, Kangtai Bio, Mindray Medical, etc. This week’s medical biometric index rose 0.3%, about 4 ahead of the CSI 300 Index.0 single, the pharmaceutical sector is generally strong; from the perspective of sub-sectors, pharmaceutical commerce, traditional Chinese medicine and biological products are better, medical services, chemical agents and APIs are weaker; in terms of stocks, Lukang Medicine (+ 46%),Sihuan Biological (Protection of Rights) (+ 46%), Unicyclic Pharmaceuticals (+ 46%) led the increase; Yanan Bikang (-26%), Jinyu Medical (-16%), Jiaoda Onli (-15%)) And other adjustments are obvious.On the whole, pharmaceutical stocks have rebounded significantly, showing rich characteristics. Specific investment strategies: 1) Fully focus on high-quality medical equipment and orthopedics, recommend Kailitai + Dabo Medical, focus on Aikang Medical + Chunli Medical, etc .; endoscopic diagnosis and treatment, focus on Nanwei Medical, etc .; cardiovascularIn the field, we mainly recommend Lepu Medical, Xinmai Medical, Qiming Medical, etc .; in the chemiluminescence field, we recommend Mindray Medical, Antu Bio, Mike Bio, Promen Technology, etc .; in the hemodialysis field, we recommend Jianfan Bio, etc. 2)Innovation is a strategic investment direction, with key recommendations: Hengrui Medicine (600276), WuXi AppTec (603259), China Biopharmaceutical (1177), Tiger Pharmaceuticals (300347) and Medicine Stone Technology (300725), etc .; 3) Not subject to policyConsumption and medical service sectors that have limited impact and have sustained high growth performance. Key recommendations are: Changchun High-tech (000661), Zhifei Bio (300122), Kangtai Bio (300601), Aier Ophthalmology (300015), and Meinian Health (002044).4) Equipment benefit classification, diagnosis and treatment expansion and product technology upgrade, key recommendations: Mindray Medical (300760), Nanwei Medical (688) 029)，Dunlop Medical (300,003) and nine strong biological (300,406) and so on. 5) In the field of pharmacies, we mainly recommend Dashenlin (603233) and ordinary people (603833). 2.2 Medium and long-term strategy: adhere to the three main lines 1) Innovation: The official launch of science and technology innovation board, innovation as a strategic investment direction: Key recommendations: 1) Innovative pharmaceutical companies: Hengrui Pharmaceutical (a model of domestic innovation), China Biopharmaceutical (a model of domestic innovation))) And Kelun Pharmaceutical (a benchmarking enterprise that benefits from procurement and consistent transformation to innovation); 2) Innovation service industry: Medicine Stone Technology (the most innovative industry, performance is exploding), WuXi PharmaTech (completely layout CRO before CROIn the latter stage of the industry chain, the leader is Hengqiang), Tiger Pharmaceuticals (service + investment, innovative medicine quadratic) and Yaoshi Technology (chemical medicine small molecule building block leader); 2) Consumption: Avoid policy disturbance, and adhere to the performance ofWang, both offensive and defensive: Key recommendations: Changchun High-tech and Anke Bio (growth hormone to meet the needs of Chang Gao), Kang Tai Bio (heavy-weight self-funded second-class vaccine), Zhifei Bio (HPV vaccine to meet female cancer prevention), Pien Tze Huang (Sustained and rapid growth of liver protection and liver protection national top secret formula brand Chinese medicine), Wuwu Bio (desensitization preparation to improve quality of life), Opcon (preventing myopia的Orthokeratology and Aier Ophthalmology (a self-funded project, a leading chain of ophthalmic medical services to improve the quality of life), Meinian Health (continually expanding health awareness, group examinations and individual examinations can permanently increase potential, black swan incident; leading 3) equipment: Benefits of tiered diagnosis and treatment expansion and product technology transformation and upgrading continue to grow rapidly, medical equipment and in vitro diagnostics are deterministic directions: Key recommendations: Mindray Medical (representing the industry leader in the rise of manufacturing in China), Yuyue Medical (the most benefiting aging householdEquipment leader), Nanwei Medical (domestic endoscope diagnosis and treatment consumable leader, performance is growing at a high speed), Wanfu Biological (POCT leader, Yaki continues to grow rapidly), Mike Bio (I3000 is expected to become the company’s explosive product) and Jiuqiang Bio(Domestic biochemical diagnostic reagent leader, product line and sales channels may be expanded one after another). 2.In March, the key combination performance was Hengrui Medicine (600276): an absolute leader in domestic innovation, and China Biopharmaceutical Model (1177).HK): Oncology drug line volume exceeded expectation, Chinese innovative pharmacopoeia model WuXi AppTec (603259): integrated innovation research and development enabling platform, the country encourages the rapid growth of innovation dividend Changchun High-tech (000661): the leader of the growth hormone industry, governanceThe well-structured next performance and simultaneous improvement of expectations; Zhifei Biological (300122): both research and development and sales, the domestic vaccine industry leader; Kangtai Biological (300601): Hengrui in the vaccine industry, 2019 is the year of breakthrough progress in research and developmentHualan Biological (002007): private leader in blood products, flu may once again drive the company’s performance outbreak; Mei Nian Health (002044): the leading domestic health checkup, the inflection point in the third quarter is obvious. Brief comment on portfolio income: The overall portfolio grew by 3 this week.0%, outperformed the market 4.2 digits, outperforming the pharmaceutical index 0.2 averages.Since the beginning of the month, the combination has outperformed the CSI 300 Index by 8.9%, underperforming the medical biological index 2.0%. 2.4 January combination 1) January core combination: Hengrui Medicine (600276): Absolute leader in domestic innovation, Chinese model of innovative medicine; China Biopharmaceutical (1177.HK): Oncology drug volume is higher than expected, a model of innovative Chinese medicines; WuXi AppTec (603259): an integrated innovation research and development enabling platform, the state encourages rapid growth in innovation dividends; Changchun High-tech (000661): a leader in the growth hormone industry, The governance structure improves the next performance and estimated simultaneous growth; Zhifei Biological (300122): both research and development and sales, the domestic vaccine industry leader; Kangtai Biological (300601): Hengrui in the vaccine industry, 2019 is the breakthrough in research and development progressYears; Hualan Biological (002007): private leader in blood products, flu may once again drive the company’s performance outbreak; Yuyue Medical (002223): domestic household medical device leader, underestimated the subject of solid income. 2) Offensive combination of small market value: Kellett (300326): Actively focus on big orthopedics, the industry and the company’s double turning point is upward; Medicine Stone Technology (300725): the leader of internal molecular accumulation blocks, and promote accelerated growth after completion of promotion. Lingrui Pharmaceutical (600285): Q3’s steady growth and simultaneous development of orthopedics + sports medicine; Dongcheng Pharmaceutical (002675): Nuclear medicine continues to grow steadily and is expected to be reassessed by the market. Brief comment on portfolio income: Last week, the overall portfolio (small market capitalization) fell by 4.3%, underperformed the market by 0.7 digits, underperforming medical index 4.7 averages.Since the beginning of the month, the combination has underperformed the market by 0.4%, outperforming the pharmaceutical bio-index 6.6%. 3 Secondary performance of the pharmaceutical industry 3.1 Industry and individual stocks rose and fell This week, the biomedical index increased by 0.3%, outperformed CSI 300 by about 4.Zero digits, of which the medical business has the largest increase of about 4.7%, medical services fell 3.5%. The top five stocks with gains were: Lukang Pharmaceutical, Sihuan Biological, Union Medical, Ogilvy Medical, Zhende Medical; the top five stocks with declines were: Yanan Bikang, Jinyu Medical, and Jiaotong University, ST Yunsheng, Yihua Health. 3.2Funds flow and block trade Southbound funds totaled 27 this week.At 3 trillion, Shanghai-Hong Kong Stock Connect gradually bought 16.500 million US dollars, Shenzhen-Hong Kong Stock Connect gradually bought 10.800 million; Northbound funds totaled 70.0 trillion, Shanghai-Hong Kong Stock Connect gradually bought 38.600 million yuan, Shenzhen-Hong Kong Stock Connect gradually bought 31.600 million yuan.Calculated based on the proportion of freely-tradable shares: The top five positions held by the medical stocks are: Yifeng Pharmacy, China Resources Sanjiu, Tiger Pharmaceuticals, Yunnan Baiyao, Aier Ophthalmology; the top five positions of the medical stocks increased by:Medical, Kelly Thai, Dean Diagnostics, Lingrui Pharmaceutical, Antu Biomedical; the top five reductions in medical land shares are: Yixintang, Kangyuan Pharmaceutical, Xinhua Pharmaceutical, Dashenlin, and Modern Pharmaceutical. A total of 13 companies in the pharmaceutical and bio-industry traded this week, with a total transaction value of 7.3 trillion, the top three transactions are Lanfan Medical, Wanfu Biological, Lai Mei Pharmaceutical. 3.3 period of financing and securities lending situation Among the top five financing specimens purchased this week, Bai Yunshan divided the first place with US $ 1 billion, followed by Lukang Medicine, Fosun Pharmaceutical, BGI, and Hengrui Medicine; this week, securities sellingIn the top five of the targets, Hengrui Medicine took 0.2 megabytes ranked first, the rest in order are microchip biological, Baiyun Mountain, Hualan Biological, Xinmai Medical. 4Recent industry policy reviewPneumococcal infections of the new type of coronavirus require legal infectious disease management On January 20, 2020, the National Health Commission issued an announcement to include pneumonitis of the new type of coronavirus infection in the management of legal infectious diseases.According to the relevant provisions of the “Prevention of Infectious Diseases Law”, according to the current knowledge of the pathogens, epidemiology, and clinical characteristics of pneumonitis infected by the new coronavirus, it is reported to the State Council for approval, and the National Health and Health Committee decides:Infected pneumonia replaces the Class B infectious diseases stipulated in the Law of the People’s Republic of China on the Prevention and Control of Infectious Diseases, and measures for the prevention and control of Class A infectious diseases are adopted.Second, pneumonia infected with the new type of coronavirus is divided into the management of quarantine infectious diseases as stipulated in the Frontier Health and Quarantine Law of the People’s Republic of China.3. At the same time, it is required that people’s governments, health and health administration departments, other government departments, and medical and health institutions can adopt a series of prevention and control measures such as patient isolation and treatment, close contact isolation and medical observation to prevent the spread of pneumonia epidemic of new coronavirus infection.The Medical Insurance Bureau issued a document stating that the new pneumonia-covered drugs should be temporarily supplemented with medical insurance payments. The National Medical Insurance Bureau decided to further strengthen the guidance to medical insurance departments in Hubei and other places, requiring the national medical insurance system to provide treatment guarantees in accordance with the “two guarantees” to ensure that patients do not suffer from cost problems.Failure to provide timely medical treatment to ensure that designated medical institutions do not affect medical treatment due to medical insurance plan budget management regulations.In response to the characteristics of the epidemic, the Medical Insurance Bureau decided to adopt a special reimbursement policy for patients diagnosed with “new coronavirus infection pneumonia”.First, all the medicines and medical service items covered by the National Health and Health Commission’s “Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection” will temporarily replace the medical insurance fund payment scope.The second is to ensure the timely payment of patients ‘expenses, especially to play the role of bottom-line protection of medical assistance funds, to alleviate patients’ medical concerns.For patients who seek medical treatment in different places, they will be treated first and then settled. Reimbursement will no longer be subject to the reduction of the proportion of out-of-town medical treatment payment reduction rules to reduce the risk of contagion caused by patient mobility.Third, for hospitals under centralized treatment, the medical insurance department will reduce the pressure on advance payment of hospital funds, and patients’ medical expenses will no longer need hospital budget control indicators.At present, there are no effective antiviral drugs, x-interferon nebulization therapy, lopinavir / ritonavir treatment can be tried, and antibacterial drugs should be used in time when there is a secondary bacterial infection.”Pneumonitis diagnosis and treatment plan (trial)”, the current treatment plan is divided into general treatment and severe treatment.General treatment: 1.Rest in bed, support treatment and ensure sufficient time; pay attention to water and electrolyte balance to maintain internal environment stability; monitor vital signs, refer to oxygen saturation, etc.2.Monitor blood routine, urine routine, C-reactive egg according to the condition, biochemical indicators (liver enzyme, myocardial enzyme, renal function, etc.), coagulation function, and perform arterial blood gas analysis if necessary, and review chest imaging.3, oxygen therapy: nasal catheter, mask to give oxygen, if necessary, nasal high-flow oxygen therapy, non-invasive or invasive mechanical communication.4. Antiviral: There are no effective antiviral drugs.Try x-interferon nebulization, lopinavir / ritonavir treatment.5. Antibacterial drugs: Avoid blind or inappropriate use of antibacterial drugs, and timely apply antibacterial drugs when there is evidence of secondary bacterial infection.Critically ill treatment: 1. Principles of treatment: prevention and treatment of complications, treatment of underlying diseases, prevention of secondary infections, support of organ function.2. Respiratory support:> Non-invasive mechanical ventilation for 2 hours, no improvement in the condition, or the patient cannot tolerate non-invasive ventilation, increased airway secretions, severe cough, or hemodynamic instability, and should transition to invasive mechanical ventilation in time.> Invasive mechanical ventilation adopts a small tidal volume “pulmonary protective ventilation strategy” to reduce ventilator-related lung injury.> If necessary, use alveolar maneuvers, prone ventilation, high-frequency oscillatory ventilation, or extracorporeal membrane oxygenation.3. Circulation support: On the basis of sufficient fluid resuscitation, vasoactive drugs are used, and hemodynamic monitoring is performed if necessary.Urgent Notice of the General Office of the State Council on Organizing the Resumption and Scheduling of Key Materials Production Enterprises for Epidemic Prevention and ControlAgree, the relevant emergency notice is as follows: 1. The people’s governments of provinces (autonomous regions and municipalities) must effectively fulfill their main responsibilities and promptly organize the production of medical protective clothing, N95 masks, medical goggles, and negative pressure ambulances for the epidemic situation.Relevant pharmaceutical and other enterprises resumed work and resumed production.It is necessary to do a good job in all aspects of production personnel, technical personnel and related equipment, raw and auxiliary materials, funds and other support work to help enterprises solve difficulties and problems encountered in production and operation in a timely manner, and timely expand the production capacity of related products as needed.2. The State Council’s response to the new Coronavirus-infected pneumonia epidemic joint prevention and control mechanism material security group is responsible for the unified management and allocation of the above-mentioned key medical emergency prevention and control materials, and local people’s governments at all levels must not stop or call them in any name.The material security team will select special company resident personnel to key enterprises to supervise the unified allocation of materials, help the enterprise to reflect difficulties and problems in a timely manner, and cooperate with relevant departments to do a good job of product quality supervision.3. Relevant enterprises producing key medical emergency prevention and control materials shall, in accordance with the State Council ‘s material security group ‘s requirements for the joint prevention and control mechanism for the new type of coronavirus infection and pneumonia epidemic, organize the procurement of raw materials and product production, complete production tasks in a timely manner, and strengthen product quality managementTo ensure that materials meet relevant safety standards.Relevant enterprises shall timely report data such as production capacity, product inventory, etc. in accordance with the requirements of the material security group.Fourth, in order to ensure the timely production, allocation, transportation, and allocation of key medical emergency prevention and control materials, coordinate work, establish relevant work linkage mechanisms, and ensure 24-hour communication.Provincial people’s governments should determine a department (bureau) -level responsible comrade to take the lead in the connection and allocation of materials.All regions, departments and relevant enterprises should unify their thinking, improve their standing, fully understand the importance of doing a good job in emergency prevention and control supplies in key areas, effectively enhance the sense of urgency and responsibility, and do a good job in accordance with the requirements of this notice. 5 Risk warnings: Changes in industry policies or more than expected, the risk of new products entering or falling below expectations, and the volume of products falling below expectations.